Visit Mersana
2 known investors
Day One is part of Servier and develops targeted medicines for cancer patients, with a particular focus on pediatric low-grade glioma and other oncology indications. The company uses a "search & development" strategy to identify programs matched to patient needs.
BiotechDigital HealthMedical Devices
Investors · 2
In the news
- Mersana Therapeutics stock (US59045L1061): what the latest restructuring and pipeline moves mean forad-hoc-news.de · 2026
- Why Analysts See Mersana’s Story Shifting To Deal And CVR Outcomes After $1B Buyoutfinance.yahoo.com · 2025
- Mersana - 2025 Company Profile, Funding & Competitors - Tracxntracxn.com · 2021
- Mersana Therapeutics Raises $65 Million in Gross Proceeds Through its At-the-Market Facilityglobenewswire.com · 2020
- Mersana Therapeutics raises $27mboston.com · 2012
- Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates | Fierce Biotechfiercebiotech.com · 2012